We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05096481
Recruitment Status : Not yet recruiting
First Posted : October 27, 2021
Last Update Posted : August 12, 2022
Sponsor:
Information provided by (Responsible Party):
Nationwide Children's Hospital

Brief Summary:

This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG) as well as recurrent medulloblastoma (MB).

PEP-CMV is a vaccine mixture of a peptide referred to as Component A. Component A is a synthetic long peptide (SLP) of 26 amino acid residues from human pp65. The SLPs encode multiple potential class I, class II, and antibody epitopes across several haplotypes. Component A will be administered as a stable water:oil emulsion in Montanide ISA 51.

Funding Source - FDA OOPD


Condition or disease Intervention/treatment Phase
High Grade Glioma Diffuse Intrinsic Pontine Glioma Recurrent Medulloblastoma Biological: PEP-CMV Drug: Temozolomide Biological: Tetanus Diphtheria Vaccine Phase 2

Detailed Description:

This phase II clinical trial will have 3 strata in order to assess the efficacy of a highly immunogenic CMV-directed peptide vaccines in children with (1) recurrent medulloblastoma (rMB), (2) newly-diagnosed high-grade gliomas (HGG) and (3) newly-diagnosed diffuse intrinsic pontine glioma (DIPG). Each stratum will run independently with a different endpoint and statistical design.

Within each stratum, the populations that may be used for analysis are defined as:

  • Safety Analysis: Patients who receive at least 1 dose of the treatment will be used for safety analyses.
  • Efficacy Analysis: Patients who receive at least 1 dose of the treatment will be used for efficacy analyses.

Stratum I: Patients with recurrent medulloblastoma with measurable disease (see eligibility) can be enrolled at any point following recurrence regardless of any prior therapy. For the purpose of this study, recurrence will be defined as a new lesion confirmed by biopsy or resection, positive cerebrospinal fluid (CSF) cytology, or recurrent/progressive tumor on MRI.

Strata II and III: Patients with newly-diagnosed high-grade glioma or DIPG may be enrolled any time within 42 days after completing radiation.

Cycle 1 (Induction cycle) is 77±2 days. Patients will receive one course of temozolomide 200 mg/m2/day x 5 days on Days 1-5 of cycle 1 and receive PEP-CMV vaccine intradermally at dose level 1 (250 μg/m2 ) on Days 21, 35 ±2 days, and 49 ±2 days. After the induction cycle which is 77 ± 2 days, each subsequent cycle is 28 days. Starting in cycle 2, PEP-CMV vaccine is administered intradermally every 28 days on day 1 of each course. Patient can continue to receive PEP-CMV every 28 days for a total of 24 cycles.

Patients will receive a tetanus (Td) booster (Td 5 flocculation units, Lf) at the time of enrollment. Immunotherapy begins with a Td pre-conditioning vaccine (Td 1 Lf, in 0.4 mL of saline) delivered i.d. at the RIGHT groin site of the vaccine injection 6-24 hours prior to the first vaccine on day 21.

The PEP-CMV vaccine will be administered as follows: 250 µg/m2 (up to a maximum of 500 µg) of Component A mixed with Montanide ISA-51 (1:1 volume ratio) intradermally administered half in the RIGHT groin and half in the LEFT groin.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 2 Trial of a Novel Peptide Vaccine (PEP-CMV) Targeting CMV Antigen for Newly Diagnosed Pediatric High-grade Glioma and Diffuse Intrinsic Pontine Glioma and Recurrent Medulloblastoma
Estimated Study Start Date : November 15, 2022
Estimated Primary Completion Date : November 15, 2026
Estimated Study Completion Date : November 15, 2028


Arm Intervention/treatment
Experimental: PEP-CMV
Participants will receive standard chemotherapy with temozolomide for five days, followed by the study vaccine, PEP-CMV, on day 21. Participants will receive a tetanus diphtheria (Td) booster vaccine and a small dose Td preconditioning vaccine to prepare their immune system to receive their first PEP-CMV vaccine. Participants will receive the first 3 PEP-CMV vaccines every 2 weeks, and after the third vaccine, the rest of the vaccines will be given monthly. The first cycle is 77 days and all subsequent cycles are 28 days. The PEP-CMV vaccine may be received for up to 24 cycles.
Biological: PEP-CMV
The PEP-CMV vaccine will be administered as follows: 250 µg/m2 (up to a maximum of 500 µg) of Component A mixed with Montanide ISA-51 (1:1 volume ratio) intradermally administered half in the RIGHT groin and half in the LEFT groin.

Drug: Temozolomide
Patients will receive one course of temozolomide 200 mg/m2/day x 5 days on Days 1-5 of cycle 1
Other Name: TMZ

Biological: Tetanus Diphtheria Vaccine
Patients will receive a tetanus (Td) booster (Td 5 flocculation units, Lf) at the time of enrollment. Immunotherapy begins with a Td pre-conditioning vaccine (Td 1 Lf, in 0.4 mL of saline) delivered i.d. at the RIGHT groin site of the vaccine injection 6-24 hours prior to the first vaccine on day 21.
Other Name: Td




Primary Outcome Measures :
  1. 4 months progression-free survival (PFS) in patients with recurrent medulloblastoma treated with radiotherapy treated with PEP-CMV [ Time Frame: 4 months ]
    Defined as the time from diagnosis until the date of disease progression

  2. 1-year PFS distribution in patients with newly diagnosed HGG treated with radiotherapy followed by PEP-CMV [ Time Frame: 1 year ]
    Defined as the time from diagnosis until the date of disease progression

  3. 1-year OS distribution in patients with newly diagnosed DIPG treated with radiotherapy followed by PEP-CMV [ Time Frame: 1 year ]
    Defined as the time from initiation of therapy to the date of death


Secondary Outcome Measures :
  1. Objective response rate in patients with recurrent medulloblastoma treated with PEP-CMV and to further define treatment related toxicities of this regimen and to further define treatment related toxicities of this regimen [ Time Frame: 2 years ]
    Objective response rate = partial response (PR) + complete response (CR)

  2. 1-year PFS in patients with recurrent medulloblastoma treated with PEP-CMV [ Time Frame: 1 year ]
    Defined as the time from diagnosis until the date of disease progression

  3. 2-year OS in patients with HGG treated with treated with radiotherapy followed by PEP-CMV [ Time Frame: 2 years ]
    Defined as the time from initiation of therapy to the date of death



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   3 Years to 25 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria for patients with recurrent /progressive medulloblastoma (stratum I)

  1. Age: Patients must be ≥3 and ≤25 years of age at the time of study enrollment
  2. Diagnosis: Recurrent medulloblastoma: Patients must have a diagnosis of medulloblastoma that is recurrent, progressive or refractory. All patients must have histological verification of a medulloblastoma, at original diagnosis or relapse.

    • Patients must have adequate pretrial tumor material available
    • Patients must have measurable disease defined as a lesion that can be measured in two perpendicular diameters on MRI.
  3. Metastatic Disease: Patients with M+ disease are eligible.
  4. Performance Status:

    Karnofsky ≥ 50% for patients >16 years of age or Lansky ≥ 50 for patients ≤ 16 years of age. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score. See Appendix I.

    Adequate neurologic function defined as:

    • Patients with neurological deficits should have deficits that are stable for a minimum of 2 weeks prior to enrollment.
    • Patients with current seizure disorders may be enrolled if seizures are well-controlled on antiepileptic therapies.
  5. Prior Therapy:

    1. Radiotherapy: prior radiotherapy requirements Patients must have received prior disease-directed therapy including radiotherapy for their initial diagnosis of medulloblastoma unless patients are less than 4 years of age at the time of enrollment.

      For those less than 4 years of age at the time of enrollment, prior disease directed therapy does not have to include prior radiotherapy.

      Patients must have had their last fraction of:

      • Craniospinal irradiation, total body irradiation or radiation to ≥ 50% of pelvis > 3 months prior to enrollment.
      • Focal irradiation > 4 weeks prior to enrollment
    2. Myelosuppressive anticancer therapy: Patients must have received their last dose of myelosuppressive anticancer therapy at least 21 days prior to enrollment
    3. Immunotherapy: Patients must have received their last dose of any immunotherapy agents at least 30 days prior to enrollment
    4. Non-myelosuppressive anticancer agents: Patients must have received their last dose of non-myelosuppressive anticancer agents at least 7 days prior to study enrollment.
    5. Antibodies: Patients must have received their last dose of any antibodies at least 21 days prior to enrollment.
    6. Hematopoietic growth factors: Patients must have received their last dose of hematopoietic growth factors at least 14 days prior to enrollment for a long-acting growth factor (e.g. pegfilgrastim) or 7 days prior to enrollment for short-acting growth factor.
    7. Autologous stem cell infusion: At least 90 days must have elapsed after an autologous stem cell infusion
  6. Organ Function Requirements:

    1. Adequate bone marrow function defined as:

      • ANC (Absolute neutrophil count) ≥ 1000/µl.
      • Platelets ≥ 75,000/µl.
      • Hemoglobin > 8 g/dL. (may be supported)
    2. Adequate Renal Function defined as: Creatinine clearance or radioisotope GFR ≥ 70ml/min/1.73 m2 or A serum creatinine based on age/gender as follows:

      Age: Maximum Serum Creatinine (mg/dL)

      • 2 to < 6 years: 0.8 (Male) 0.8 (Female)
      • 6 to < 10 years: 1 (Male) 1 (Female)
      • 10 to < 13 years: 1.2 (Male) 1.2 (Female)
      • 13 to < 16 years: 1.5 (Male) 1.4 (Female)
      • ≥ 16 years: 1.7 (Male) 1.4 (Female)
    3. Adequate Liver Function Defined as

      • Total bilirubin ≤1.5 times institutional ULN
      • AST(SGOT) ≤3 × institutional upper limit of normal
      • ALT(SGPT) ≤3 × institutional upper limit of normal
    4. Patients of childbearing or child-fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study.
    5. Signed informed consent according to institutional guidelines must be obtained prior to registration.

Inclusion Criteria for Patients with Newly-Diagnosed High-Grade Gliomas (HGG) (stratum II) and Newly-Diagnosed (DIPG) (stratum III)

  1. Age: Patients must be ≥3 and ≤25 years of age at the time of study enrollment
  2. Diagnosis

    1. Stratum II: patients must have histologically confirmed, newly-diagnosed HGG (such as anaplastic astrocytoma, glioblastoma, H3K27M mutant diffuse midline glioma, etc.).

      • Patients with a newly-diagnosed HGG must enroll within 6 weeks of their final dose of standard radiation therapy with or without chemotherapy.
      • Patients with primary spinal cord tumors are eligible
    2. Stratum III: Patients with a newly-diagnosed DIPG:

      • Patients with a radiographically typical DIPG, defined as a tumor with a pontine epicenter and diffuse involvement of more than 2/3 of the pons, are eligible without histologic confirmation.
      • Patients with brainstem lesions that do not meet these radiographic criteria will be eligible if there is histologic confirmation of an infiltrating astrocytoma WHO grades II-IV.
  3. Metastatic Disease: Patients with M+ disease are eligible.
  4. Performance Status:

    Karnofsky ≥ 50 for patients > 16 years of age and Lansky ≥ 50 for patients ≤ 16 years of age (See Appendix I). Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.

    Adequate neurologic function defined as:

    • Patients with neurological deficits should have deficits that are stable for a minimum of 1 week prior to enrollment.

  5. Prior Therapy requirements: Patients must have received no prior therapy other than surgery, radiation, chemotherapy during radiotherapy and/or steroids (dexamethasone with goal to wean dexamethasone throughout protocol therapy).

    Patients with a newly diagnosed high-grade glioma or DIPG must enroll within 6 weeks of their final dose of standard of care radiation therapy with or without chemotherapy.

    1. Patients with HGG or DIPG are permitted, but not required, to have received chemotherapy during radiation. Bevacizumab is permitted prior to enrollment in patients with DIPG or HGG. Patients must have received their last dose of bevacizumab at least 14 days prior to enrollment.
    2. For HGG patients, Patients must have received radiotherapy at a standard dose of 54 Gy in 1.8 Gy fractions for approximately 6 weeks with an acceptable variance of 10%. Radiation therapy must have begun no later than 30 days after the date definitive surgery.
    3. Patients must enroll within 42 days of their final dose of standard radiation therapy
    4. For patients with DIPG, Patients must have received radiotherapy at a standard dose of radiotherapy of 54 Gy in 1.8 Gy daily fractions for approximately 6 weeks with an acceptable variance rate of 10%. Radiation therapy must have begun no later than 30 days after the date of radiographic diagnosis or biopsy
    5. For patients with spinal cord HGG: Patients must have received radiotherapy at a standard dose of 54 Gy in 1.8 Gy fractions for approximately 6-7 weeks with an acceptable variance of 10%
    6. For patients with metastatic disease: Patients may have received standard dose craniospinal therapy
  6. Organ Function Requirements:

    1. Adequate bone marrow function defined as

      • ANC (Absolute neutrophil count) ≥ 1000/µl.
      • Platelets ≥ 75,000/µl.
      • Hemoglobin > 8 g/dL. (may be supported)
    2. Adequate Renal Function defined as: Creatinine clearance or radioisotope GFR ≥ 70ml/min/1.73 m2 or A serum creatinine based on age/gender as follows:

      Age: Maximum Serum Creatinine (mg/dL)

      • 2 to < 6 years: 0.8 (Male) 0.8 (Female)
      • 6 to < 10 years: 1 (Male) 1 (Female)
      • 10 to < 13 years: 1.2 (Male) 1.2 (Female)
      • 13 to < 16 years: 1.5 (Male) 1.4 (Female)
      • ≥ 16 years: 1.7 (Male) 1.4 (Female)
    3. Adequate Liver Function Defined as:

      • Total bilirubin ≤1.5 times institutional ULN
      • AST(SGOT) ≤3 × institutional upper limit of normal
      • ALT(SGPT) ≤3 × institutional upper limit of normal
    4. Patients of childbearing or child-fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study.
    5. Signed informed consent according to institutional guidelines must be obtained prior to registration.

Exclusion Criteria for all strata:

  1. Pregnancy or Breast-Feeding:

    1. Pregnant or breast-feeding women will not be entered on this study due to known or unknown risks of fetal and teratogenic adverse events as seen in animal/human studies. Pregnancy tests must be obtained in girls who are post-monarchal. Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.
    2. Pregnancy Prevention Patients of childbearing or child fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study and for 3 months after drug cessation.
  2. Study Specific:

    1. Active infection requiring treatment
    2. Patients with malignancy related to HIV or solid organ transplant: known history of HIV, HBV surface antigen positivity or positive HCV antibody are not eligible. Viral testing is not required unless clinically indicated in patients without a known history
    3. Known immunosuppressive disease
    4. Patients with active renal, cardiac (congestive cardiac failure, myocardial infarction, myocarditis), or moderate to severe pulmonary problems generally defined by need for medical intervention (e.g., oxygen, medications) and/or limiting activities of daily living (generally CTCAE Grade 2 or higher) or shortness of breath with limited exertion are not eligible. Pulmonary conditions include (but are not limited to) COPD, asthma, and hemi-pneumectomy
    5. Patients receiving concomitant immunosuppressive agents for medical conditions; inhaled corticosteroids for asthma are allowed.
    6. Patients receiving concomitant tumor-directed therapy
    7. Patients receiving any other investigational drug therapy.
    8. Patients on dexamethasone > 0.1 mg/Kg/day up to maximum dose of 4 mg/day or equivalent.
    9. Patients with any clinically significant unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction).
    10. Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy
    11. Patients at high risk for imminent neurologic decline due to extensive bulk disease, midline shift, or herniation on MRI. These patients should be discussed with the study chairs.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05096481


Contacts
Layout table for location contacts
Contact: Dorothy Crabtree 614-722-8693 dorothy.crabtree@nationwidechildrens.org

Locations
Layout table for location information
United States, Colorado
Children's Hospital Colorado
Aurora, Colorado, United States, 80045
Contact: Kathleen Dorris, MD    720-777-8314    kathleen.dorris@childrenscolorado.org   
Principal Investigator: Kathleen Dorris, MD         
United States, District of Columbia
Children's National Medical Center
Washington, District of Columbia, United States, 20010
Contact: Eugene Hwang, MD    202-476-5046    ehwang@childrensnational.org   
Principal Investigator: Eugene Hwang         
United States, Illinois
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States, 60611
Contact: Ashley Plant, MD    312-227-4090    aplant@luriechildrens.org   
Principal Investigator: Ashley Plant, MD         
United States, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Contact: Karen Wright, MD    617-632-4309    KarenD_wright@dfci.harvard.edu   
Principal Investigator: Karen Wright, MD         
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
Contact: Eric Thompson, MD    919-684-5013    pedsneuronc@duke.edu   
Principal Investigator: Eric Thompson, MD         
United States, Ohio
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States, 45229
Contact: Peter de Blank, MD    513-517-2068    Peter.deBlank@cchmc.org   
Principal Investigator: Peter de Blank, MD         
Nationwide Children's Hospital
Columbus, Ohio, United States, 43205
Contact: Melinda Triplet    614-722-6039    melinda.triplet@nationwidechildrens.org   
Principal Investigator: Maryam Fouladi, MD         
United States, Pennsylvania
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104
Contact: Michael J Fisher, MD    215-590-5188    fisherm@email.chop.edu   
Principal Investigator: Michael J Fisher, MD         
United States, Texas
Texas Children's Hospital
Houston, Texas, United States, 77030
Contact: Patricia Baxter, MD    832-824-4681    pabaxter@txch.org   
Principal Investigator: Patricia Baxter, MD         
United States, Washington
Seattle Children's Hospital
Seattle, Washington, United States, 98105
Contact: Sarah Leary, MD    206-987-2106    sarah.leary@seattlechildrens.org   
Principal Investigator: Sarah Leary, MD         
Sponsors and Collaborators
Nationwide Children's Hospital
Investigators
Layout table for investigator information
Study Chair: Eric Thompson, MD Duke University
Study Chair: Daniel Landi, MD Duke University
Study Chair: Maryam Fouladi, MD Nationwide Children's Hospital
Layout table for additonal information
Responsible Party: Nationwide Children's Hospital
ClinicalTrials.gov Identifier: NCT05096481    
Other Study ID Numbers: CONNECT1906
R01FD007283 ( U.S. FDA Grant/Contract )
First Posted: October 27, 2021    Key Record Dates
Last Update Posted: August 12, 2022
Last Verified: April 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Nationwide Children's Hospital:
High Grade Glioma
Diffuse Intrinsic Pontine Glioma
Recurrent Medulloblastoma
Immunotherapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Glioma
Medulloblastoma
Diffuse Intrinsic Pontine Glioma
Recurrence
Disease Attributes
Pathologic Processes
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neuroectodermal Tumors, Primitive
Brain Stem Neoplasms
Infratentorial Neoplasms
Brain Neoplasms
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Temozolomide
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents